Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is a company with a strong cash position and a positive outlook for growth, evidenced by their record-breaking 1Q26 financial results and 27% YoY revenue growth. With the recent FDA approval of their avance nerve allograft as a biologic, Axogen's market positioning has been further strengthened, and their products are now available in the majority of the country. Based on their projected sales and revenue growth, we believe that the current stock price does not accurately reflect the company's potential for continued expansion and success in the peripheral nerve repair market.

Bears say

Axogen is currently reporting a net loss for the year, despite a significant increase in revenue. This trend indicates that the company has not been able to effectively manage its expenses and achieve profitability, which could negatively affect its long-term financial stability. Additionally, the company's high reliance on investments in commercial infrastructure raises concerns about its future profitability and potential cash flow issues.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.